Deep Intelligent Pharma

Deep Intelligent Pharma is a Singapore based AI Clinical Trial Company

Active

Updated: Feb 17, 2026 ·

About

Deep Intelligent Pharma is a Singapore-based AI clinical trial company focused on transforming pharmaceutical research and development. The company leverages an AI-native multi-agent platform designed to automate complex clinical trial workflows, thereby enhancing efficiency in the drug development process.

This innovative platform integrates advanced artificial intelligence to streamline various stages of pharmaceutical R&D. By applying its technology, Deep Intelligent Pharma seeks to accelerate the introduction of new pharmaceutical products to market, contributing to capital efficiency within the biotech sector.

Recent News & Mentions

Feb 2, 2026FundingDeep Intelligent Pharma - Series D

Financial History

Deep Intelligent Pharma has raised $60.0M across 1 funding round. Most recently, it raised $60.0M Series D in February 2026.

Total Raised

$60.0M

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Feb 5, 2026	Imbioray	$28.8M Series B	Deep Intelligent Pharma	Hainan Yuque Investment, Hangzhou Xiner Technology, Shen Yousheng

Funding Rounds Raised

Date	Round	Lead Investors	Other Investors
Feb 2, 2026	$60.0M Series D		CDH Investments, Jinyi Capital, Kaitai Capital, Trustar Capital, Xin Ding Capital

Financial History

Deep Intelligent Pharma has raised $60.0M across 1 funding round.

Total Raised

$60.0M

Valuation

N/A

Deep Dive

Deep Intelligent Pharma is a private startup operating from its headquarters in Singapore. The company is identified as an AI clinical trial company, with a strategic focus on integrating artificial intelligence to innovate and optimize processes within the pharmaceutical industry. Its core mission revolves around enhancing the efficiency and effectiveness of drug development, addressing critical challenges faced in bringing new therapies to market.

The foundation of Deep Intelligent Pharma's technological approach is its revolutionary AI-native multi-agent platform. This advanced system is specifically engineered to transform pharmaceutical research and development by introducing sophisticated AI capabilities across the entire drug discovery and development lifecycle. The platform's design emphasizes intelligent automation, predictive analytics, and data-driven insights to improve decision-making and operational execution.

A key application of this platform involves the automation of clinical trial workflows. By streamlining these inherently complex and time-consuming processes, Deep Intelligent Pharma aims to significantly reduce the operational burden, minimize human error, and accelerate the timelines typically associated with clinical research. This efficiency gain is crucial for bringing new pharmaceutical products to market more rapidly and cost-effectively.

Furthermore, Deep Intelligent Pharma positions its AI-driven solutions as a catalyst for fostering capital efficiency within the broader biotech sector. The company's technology enables biotech firms, particularly highlighted in regions such as China, to achieve substantial progress and innovation with a more optimized deployment of financial resources. This contributes to what the company describes as a "DeepSeek moment" in the industry, signifying a breakthrough in capital-efficient development and a more agile approach to drug discovery.

Sources

Frequently Asked Questions

What specific technological approach does Deep Intelligent Pharma utilize in clinical trials?

Deep Intelligent Pharma employs an AI-native multi-agent platform designed to transform pharmaceutical R&D and automate clinical trial workflows.

How does Deep Intelligent Pharma aim to impact pharmaceutical research and development?

The company aims to transform pharmaceutical R&D by automating clinical trial workflows, which contributes to increased efficiency and potentially faster drug development cycles.

Does Deep Intelligent Pharma have a particular focus on any regional biotech markets?

Yes, the company's solutions are noted for driving capital efficiency in the biotech sector, with specific mention of its impact within China's biotech landscape.